Real World Experience of Denosumab Treatment in the Belfast Osteoporosis Service

Osteoporosis is a significant global health and economic burden associated with bone fracture, morbidity and mortality. Denosumab, a novel human monoclonal antibody second-line treatment, inhibits osteoclast-mediated bone resorption and increases bone mineral density (BMD). Treatment achieves reduct...

Descripción completa

Detalles Bibliográficos
Autores principales: Moran, CP, English, S, Beringer, TRO, Lindsay, JR
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Ulster Medical Society 2019
Materias:
Clinical Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790640/
https://www.ncbi.nlm.nih.gov/pubmed/31619848

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790640/
https://www.ncbi.nlm.nih.gov/pubmed/31619848

Ejemplares similares